- Doctors & Departments
- Conditions & Advice
- Your Visit
- Research & Innovation
The Gastrointestinal Eosinophilic Diseases Program (GEDP) provides state-of-the-art, multidisciplinary care to patients affected by eosinophilic gastrointestinal diseases (EGIDs), including eosinophilic esophagitis (EoE).
Our team of medical professionals conducts leading-edge research, and we are the only multidisciplinary program caring for children with EGIDs in the Midwestern United States and Rocky Mountain region. Plus, our GEDP is one of the few programs in the country to include feeding specialists and behavioral health professionals in a team approach of treating children with EGIDs. We gladly accept referrals from across the nation.
At Children's Colorado, patients and families are provided with the latest in clinical services ranging from endoscopic assessment, allergy testing, and in some circumstances, novel treatment protocols. A wide range of clinical research projects are being conducted to uncover new knowledge and improve patient care. Interested patients are offered the opportunity to participate in any protocol.
The GEDP team conducts innovative research focusing on eosinophils’ impact on the gastrointestinal tract. Studies center on the mechanisms that eosinophils relate to resident cells of the intestinal tract and how these relationships contribute to host health and disease.
EGIDs are a group of diseases characterized by a wide variety of gastrointestinal symptoms including vomiting, swallowing problems, food impaction, abdominal pain, diarrhea, slow growth and bleeding. These symptoms occur in combination with increased numbers of eosinophils in the gastrointestinal lining. Eosinophils are a type of white blood cell that has been primarily associated with allergic diseases but are also found in other diseases.
Depending on the part of the GI tract affected, EGIDs can be called a variety of different names, such as eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC), with the diagnostic term being based primarily on the location of the mucosal eosinophilia.
The mission of the Gastrointestinal Eosinophilic Diseases Program is to improve the quality of life for patients and families affected by EGIDs. Our team offers comprehensive evaluation for patients suspected of having EGIDs and for children who have a previously established diagnosis. Patients referred to the program will receive:
Treatment options are reviewed and discussed in detail with families and their physicians. Appropriate education and support is provided. Follow up occurs by telephone and during future appointments.
Research protocols that seek to determine the cause of EGIDs, offer novel treatment plans and improve the quality of care are a significant part of the mission of the GEDP. We offer interested patients the opportunity to participate in available protocols.
Our team is a part of the Mucosal Inflammation Program (MIP) in the Gastroenterology Division at the University of Colorado School of Medicine that is directed by Sean Colgan, PhD. The MIP carries an overall theme of determining mechanisms of inflammation at a variety of mucosal surfaces including the GI tract and the lung.
Together, the Gastrointestinal Eosinophilic Diseases Program and Mucosal Inflammation Program include a unique blend of basic and clinical investigators. This integration of basic and clinical sciences and multidisciplinary approach fosters collaboration between key personnel from different divisions of the University of Colorado School of Medicine to provide outstanding patient care and novel research outcomes.